By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Alkermes plc 

852 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-609-6000 Fax: n/a


SEARCH JOBS

About Alkermes plc

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes' website at http://www.alkermes.com.

Key Executives
Richard F. Pops
Chairman and Chief Executive Officer

Shane Cooke
President

Kathryn L. Biberstein
Senior Vice President, General Counsel and Secretary, and Chief Compliance Officer

Mark Stejbach
Senior Vice President, Chief Commercial Officer

Georgianna Harris
Vice President, Regulatory Affairs

Madeline D. Coffin
Vice President, Human Resources

Elliot W. Ehrich, M.D.
Senior Vice President, Research and Development, and Chief Medical Officer

James M. Frates
Senior Vice President, Chief Financial Officer

Blair C. Jackson
Vice President, Business Development

Michael J. Landine
Senior Vice President, Corporate Development

Rebecca J. Peterson
Senior Vice President, Corporate Communications

Gordon G. Pugh
Senior Vice President, Chief Operating Officer and Chief Risk Officer

Peter Norman
Vice President, Government Affairs and Policy

Srdjan Stankovic
Senior Vice President, Clinical Development and Medical Affairs

Locations

Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000

Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000

Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000

Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100

Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642


Key Statistics


Email: mediainfo@alkermes.com
Ownership: Public

Web Site: Alkermes plc
Employees: 1,200
Symbol: ALKS
 




Segment
Drug Delivery





Company News
2015 Could Be Blockbuster Year for Alkermes plc (ALKS), Says Citi 12/17/2014 3:03:51 PM
Alkermes plc (ALKS) Announces Initiation Of Clinical Study Of Extended Durations Of Aripiprazole Lauroxil For Treatment Of Schizophrenia 12/15/2014 9:12:36 AM
Alkermes plc (ALKS)’ Corporate Presentation To Be Webcast At The NASDAQ OMX 31st Investor Program 11/26/2014 8:47:44 AM
Alkermes plc (ALKS)’ Corporate Presentation To Be Webcast At The Credit Suisse 2014 Healthcare Conference 11/5/2014 9:51:25 AM
Alkermes plc (ALKS) Reports Third Quarter 2014 Financial Results 10/29/2014 9:05:15 AM
Alkermes plc (ALKS) To Host Conference Call To Discuss Third Quarter 2014 Financial Results 10/23/2014 11:33:31 AM
Alkermes plc (ALKS)’ New Drug Application For Aripiprazole Lauroxil For Treatment Of Schizophrenia Accepted For Filing By U.S. FDA 10/22/2014 9:19:19 AM
Alkermes plc (ALKS)’ Corporate Presentation To Be Webcast At Morgan Stanley (MST) Global Healthcare Conference 9/3/2014 1:56:15 PM
Alkermes plc (ALKS) Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic 9/3/2014 10:55:40 AM
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 7106 For Treatment Of Pain 8/26/2014 9:38:43 AM
12345678910...
//-->